Jmv 179

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596923

CAS#: 119386-87-7

Description: Jmv 179 is a cholecystokinin receptor antagonist.

Chemical Structure

Jmv 179
CAS# 119386-87-7

Theoretical Analysis

MedKoo Cat#: 596923
Name: Jmv 179
CAS#: 119386-87-7
Chemical Formula: C51H67N7O15S
Exact Mass: 1049.4416
Molecular Weight: 1050.19
Elemental Analysis: C, 58.33; H, 6.43; N, 9.34; O, 22.85; S, 3.05

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Jmv 179; Jmv-179; Jmv179;

IUPAC/Chemical Name: (6S,9S,15R,18S,21S)-15-((1H-indol-3-yl)methyl)-9,18-dibutyl-2,2-dimethyl-4,7,10,13,16,19-hexaoxo-21-(phenethoxycarbonyl)-6-(4-(sulfooxy)benzyl)-3-oxa-5,8,11,14,17,20-hexaazatricosan-23-oic acid


InChi Code: InChI=1S/C51H67N7O15S/c1-6-8-18-38(55-47(64)40(58-50(67)72-51(3,4)5)27-33-21-23-35(24-22-33)73-74(68,69)70)45(62)53-31-43(59)54-41(28-34-30-52-37-20-14-13-17-36(34)37)48(65)56-39(19-9-7-2)46(63)57-42(29-44(60)61)49(66)71-26-25-32-15-11-10-12-16-32/h10-17,20-24,30,38-42,52H,6-9,18-19,25-29,31H2,1-5H3,(H,53,62)(H,54,59)(H,55,64)(H,56,65)(H,57,63)(H,58,67)(H,60,61)(H,68,69,70)/t38-,39-,40-,41+,42-/m0/s1

SMILES Code: O=C(O)C[C@@H](C(OCCC1=CC=CC=C1)=O)NC([C@H](CCCC)NC([C@@H](CC2=CNC3=C2C=CC=C3)NC(CNC([C@H](CCCC)NC([C@H](CC4=CC=C(OS(=O)(O)=O)C=C4)NC(OC(C)(C)C)=O)=O)=O)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1050.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Quesada A, Micevych P. Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats. Brain Res. 2006 Feb 16;1073-1074:316-20. Epub 2006 Feb 10. PubMed PMID: 16472782.

2: Gigoux V, Escrieut C, Fehrentz JA, Poirot S, Maigret B, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy D. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin. J Biol Chem. 1999 Jul 16;274(29):20457-64. PubMed PMID: 10400673.

3: Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Fréhel D, Gully D, Vaysse N, Fourmy D. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J Biol Chem. 1997 Jan 31;272(5):2920-6. PubMed PMID: 9006937.

4: Camby I, Salmon I, Oiry C, Galleyrand JC, Nagy N, Danguy A, Brotchi J, Pasteels JL, Martinez J, Kiss R. The influence of gastrin and/or cholecystokinin antagonists on the proliferation of three human astrocytic tumor cell lines. Neuropeptides. 1996 Oct;30(5):433-7. PubMed PMID: 8923504.

5: Talkad VD, Patto RJ, Metz DC, Turner RJ, Fortune KP, Bhat ST, Gardner JD. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Biochim Biophys Acta. 1994 Oct 20;1224(1):103-16. PubMed PMID: 7524683.

6: Hadjiivanova C, Petkov VV, Kehayov R, Martinez J. Behavioural effects of two cholecystokinin analogues: JMV 236 and JMV 179. Neuropeptides. 1994 Sep;27(3):163-7. PubMed PMID: 7816187.

7: Poirot SS, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor. Mol Pharmacol. 1994 Apr;45(4):599-607. PubMed PMID: 8183238.

8: Yule DI, Williams JA. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor. Peptides. 1994;15(6):1045-51. PubMed PMID: 7527529.

9: Silvente Poirot S, Hadjiivanova C, Escrieut C, Dufresne M, Martinez J, Vaysse N, Fourmy D. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179. Eur J Biochem. 1993 Mar 1;212(2):529-38. PubMed PMID: 8444190.

10: Nagain C, Galas MC, Lignon MF, Rodriguez M, Martinez J, Rozé C. Synthetic CCK8 analogs with antagonist activity on pancreatic receptors: in vivo study in the rat, compared to non-peptidic antagonists. Pancreas. 1991 May;6(3):275-81. PubMed PMID: 1713671.